Sup-Icu RENal (SIREN)

• Status: Completed
• Trial end date: 2018-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Data show that episodes of bleeding may often be observed in critically ill patients with dialysis-dependent acute renal failure (ARF) on renal replacement therapy (RRT). From a clinical perspective, patients with dialysis-dependent ARF and end-stage renal disease (ESRD) may be considered a high risk population in regard to e.g. development of gastrointestinal (GI-) bleeding.

In the current prospective subanalysis "SIREN" of the randomized placebo-controlled clinical trial "SUP-ICU" (NCT02467621), the investigators seek to elucidate whether the subpopulation of critically ill patients with acute kidney injury requiring renal replacement therapy (RRT) benefit from prophylactic treatment with a proton-pump-inhibitor such as pantoprazole.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Inselspital, Berne
• Collaborators: Rigshospitalet, Copenhagen, Denmark (Prof. Moller, Dr. Krag); SUP-ICU Principle investigator: Dr. M. Krag, Rigshospitalet, Copenhagen, Denmark; SUP-ICU Sponsor: Dr. M.H. Moller, Rigshospitalet, Copenhagen, Denmark
• Treatments: Pantoprazole

Criteria

Inclusion Criteria:

• please refer to SUP-ICU (NCT02467621) trial

Exclusion Criteria:

• please refer to SUP-ICU (NCT02467621) trial